Dr. Peter Black is a Urologic Oncologist at Vancouver General Hospital, a Research Scientist at the Vancouver Prostate Centre, and an Associate Professor in the Department of Urologic Sciences at the University of British Columbia (UBC). He received his undergraduate degree from UBC and his medical degree from Johannes Gutenberg University in Mainz, Germany. He completed his urologic training at the University of Washington in Seattle and fellowship in urologic oncology at M.D. Anderson Cancer Center in Houston, Texas.
Dr. Black has a clinical sub-specialty interest in bladder and prostate cancer. His grant-funded translational research program focuses primarily on molecular biomarkers and targeted therapies in urothelial carcinoma. His recent work has identified genomic signatures that predict outcome after neoadjuvant chemotherapy in muscle-invasive bladder cancer, and these have recently been commercialized. He is an active clinical trialist and is currently principle investigator of a co-operative group (SWOG) trial testing atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer.
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!